Eurofins Scientific (EUFI) is expanding its high-potency active pharmaceutical ingredient manufacturing operations through its Eurofins CDMO Alphora unit based in Mississauga, Canada. The expansion targets both standard and high-potency small molecule development
More
Sandoz has struck a major deal with China’s Shanghai Henlius Biotechnology, securing commercialisation rights to three biosimilars currently in early development. The Swiss pharmaceutical company will pay up to $100.5 million upfront
More
The Massachusetts PROTECT Act, signed into law by Governor Healey on August 5, 2026, introduces significant new compliance obligations for employers operating in the state. Known formally as Chapter 163 of the
More
Mariam El-Sobky, a Lincoln’s Inn barrister, has been disbarred following a disciplinary tribunal that uncovered multiple serious professional breaches spanning several years. El-Sobky was found to have secretly recorded family court proceedings
More
A federal appeals court has dealt another blow to the Trump administration’s efforts to install loyalist prosecutors across the country’s top law enforcement offices. A three-judge Ninth Circuit panel unanimously affirmed that
More
The FTSE 100 has pulled back from its record high in recent weeks, prompting fresh debate about whether the index can reclaim that ground before summer ends. The index hit an all-time
More
Equity markets and the US dollar retreated sharply on Friday as a string of disappointing economic data releases rattled investor confidence across Wall Street. The sell-off reflected growing concern among traders that
More
The FTSE 100 extended its losing streak to six straight sessions, weighed down by weakness across consumer-facing stocks on the London Stock Exchange. The index has faced sustained selling pressure over several
More
Frasers Group has increased its holding in Hugo Boss to just under 48 per cent, falling short of full control over the German luxury fashion brand. Mike Ashley’s Sports Direct owner offered
More
AstraZeneca has reported positive phase 3 results from two separate non-small cell lung cancer trials, though the wins have done little to offset a significant setback elsewhere in its pipeline. The British
More